<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-215
Date of Submission: 2025-06-17

This report was submitted by a Other Healthcare Professional from Mcintyre, Preston and Mendoza Medical Center concerning patient ANON-PX-4980. The subject is a 85-year-old female with a significant medical history including atrial fibrillation, osteoarthritis, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Subcutaneous route at a dosage of 136mg, initiated on 2025-05-17 for Neuropathic pain and discontinued on 2025-06-15; Ibuprofen (NSAID) administered via the Intramuscular route at a dosage of 84mg, initiated on 2025-05-17 for Pain and inflammation and discontinued on 2025-06-15.

On approximately 2025-06-15, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Headache. The Dizziness was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Headache was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Experience yourself budget them short fine for. Trip tax evidence out plant pick. Whose keep nearly.</data>
report_id: ADR-2025-215
report_date: '2025-06-17'
patient_details:
  patient_id: ANON-PX-4980
  gender: Female
  relevant_history:
  - atrial fibrillation
  - osteoarthritis
  - hypertension
  age_at_reaction: 85
suspected_drugs:
- drug_name: Gabapentin
  dosage: 136mg
  route_of_administration: Subcutaneous
  start_date: '2025-05-17'
  indication_for_use: Neuropathic pain
  drug_class: Anticonvulsant
  end_date: '2025-06-15'
- drug_name: Ibuprofen
  dosage: 84mg
  route_of_administration: Intramuscular
  start_date: '2025-05-17'
  indication_for_use: Pain and inflammation
  drug_class: NSAID
  end_date: '2025-06-15'
adverse_reactions:
- symptom_name: Dizziness
  onset_date: '2025-06-15'
  severity: Moderate
  outcome: Not Recovered
  intervention_required: true
- symptom_name: Headache
  onset_date: '2025-06-15'
  severity: Moderate
  outcome: Fatal
  intervention_required: false
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Positive rechallenge
  naranjo_score: 1
reporting_facility: Mcintyre, Preston and Mendoza Medical Center
reporter_type: Other Healthcare Professional
notes: Experience yourself budget them short fine for. Trip tax evidence out plant
  pick. Whose keep nearly.
